A case of familial hypercholesterolemia caused by homozygous deletion in the LDLR gene diagnosed by targeted next-generation sequencing

References

• Youngblom E, Pariani M, Knowles JW. Familial Hypercholesterolemia. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. [Internet]. Seattle: University of Washington, Seattle; 2014 [Updated 2016]. 1993–2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK174884.
   Google Scholar
• Kasper DL, Fauci AS, Hauser S, et al. Harrison’s principles of internal medicine. 19th ed. Vol. 2. Ch 421. 2441. New York: McGraw-Hill; 2015.
   Google Scholar
• Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–268.
   PubMed Web of Science ®Google Scholar
• Martin SS, Blaha M, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061–2068.
   PubMed Web of Science ®Google Scholar
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific steering committee on behalf of the simon broome register group. Br Med J. 1991;303:893–896.
   PubMedGoogle Scholar
• Tsouli SG, Kiortsis DN, Argyropoulou MI, et al. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest. 2005;35:236–244.
   PubMed Web of Science ®Google Scholar
• Mabuchi H. Half a century tales of familial hypercholesterolemia (FH) in Japan. J Atheroscler Thromb. 2017;24:189–207.
   Web of Science ®Google Scholar
• Durrington P. Dyslipidaemia. Lancet. 2003;362:717–731.
   PubMed Web of Science ®Google Scholar
• Fahed AC, Shibbani K, Andary RR, et al. Premature valvular heart disease in homozygous familial hypercholesterolemia. Cholesterol. 2017;2017:3685265.
   PubMedGoogle Scholar
• Vongpromek R, Bos S, Ten Kate GJR, et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Int Med. 2015;278:166–173.
   PubMed Web of Science ®Google Scholar
• Marais AD, Firth JC, Blom DJ. Homozygous Familial Hypercholesterolemia and its management. Semin Vasc Med. 2004;4:43–50.
   PubMedGoogle Scholar
• Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–3490.
   PubMed Web of Science ®Google Scholar
• Dutch Lipid Network. World Health Organization. Familial hypercholesterolemia—report of a second WHO Consultation. Geneva, Switzerland: World Health Organization, 1999. (WHO publication no. WHO/HGN/FH/CONS/99.2).
   Google Scholar
• Williams RR, Hunt SC, Schumacher MC, et al. US Med Ped. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171–176.
   PubMed Web of Science ®Google Scholar
• Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidem. 2004;160:407–420.
   PubMed Web of Science ®Google Scholar
• Repas TB, Tanner JR. Preventing early cardiovascular death in Familial Hypercholesterolemia. J Am Osteopath Assoc. 2014;114:99–108.
   PubMedGoogle Scholar
• Fahed AC, Khalaf R, Salloum R, et al. Variable expressivity and co‐occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy. Mol Genetic Genomic Med. 2016;4:283–291.
   Web of Science ®Google Scholar
• Zhao M, Wang Q, Wang Q, et al. Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectives. BMC Bioinformatics. 2013;14(Suppl 11):S1.
   PubMed Web of Science ®Google Scholar
• Giugliano T, Fanin M, Savarese M, et al. Identification of an intragenic deletion in the SGCB gene through a re-evaluation of negative next generation sequencing results. Neuromuscul Disord. 2016;26:367–369.
   PubMed Web of Science ®Google Scholar
• Simard LR, Viel J, Lambert M, et al. The Delta>15 Kb deletion French Canadian founder mutation in familial hypercholesterolemia: rapid polymerase chain reaction-based diagnostic assay and prevalence in Quebec. Clin Genet. 2004;65:202–208.
   Web of Science ®Google Scholar
• Horsthemke B, Dunning A, Humphries S. Identification of deletions in the human low density lipoprotein receptor gene. J Med Genetic. 1987;24:144–147.
   Web of Science ®Google Scholar
• Nissen PH, Damgaard D, Stenderup A, et al. Genomic characterization of five deletions in the LDL receptor gene in Danish Familial Hypercholesterolemic subjects. BMC Med Genet. 2006;7:55.
   Web of Science ®Google Scholar
• Hobbs HH, Russell DW, Brown MS, et al. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Ann Rev Genet. 1990;24:133–170.
   PubMed Web of Science ®Google Scholar
• Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209:189–194.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Bruckert E, Ginsberg HN, et al. European atherosclerosis society consensus panel on familial hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146–2157.
   PubMed Web of Science ®Google Scholar
• Burns T, Breathnach S, Cox N, et al. Rook’s Textbook of Dermatology, 8th Edition. Vol. 3. 58.84–58.87. Chichester, West Sussex: Wiley-Blackwell; 2010.
   Google Scholar
• Smith RJ, Hiatt WR. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. JAMA Intern Med. 2013;173:1491–1492.
   Web of Science ®Google Scholar
• Raal FJ. Lomitapide for homozygous familial hypercholesterolaemia. Lancet. 2013;381:7–8.
   PubMed Web of Science ®Google Scholar
• Bell DA, Hooper AJ, Watts GF, et al. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc Health Risk Manag. 2012;8:651–659.
   PubMedGoogle Scholar
• Everett BM M.D, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 Inhibitors—the clinical benefit of lipid drugs. N Engl J Med. 2015;373:1588–1591.
   PubMed Web of Science ®Google Scholar
• Iyengar SS, Puri R, Narasingan SN, et al. Lipid Association of India expert consensus statement on management of dyslipidemia in Indians Part 2. Clin Lipidol. 2017;12:56–109.
   Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–160.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brandrup-Wognsen G, Palmer MK, et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res. 2010;51:1546–1553.
   PubMed Web of Science ®Google Scholar
• Neil A, Cooper J, Betteridge J, et al. Reduction in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolemia: a prospective registry study. Eur Heart J. 2008;29:2625–2633.
   PubMed Web of Science ®Google Scholar
• Iyengar SS, Puri R, Narasingan SN, et al. Lipid Association of India expert consensus statement on management of dyslipidemia in Indians: part 1. J Assoc Physicians India. 2016;64:7–52.
   Google Scholar